Anika Therapeutics Current Valuation vs. Price To Earning
| ANIK Stock | USD 17.72 0.52 3.02% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.45 | 0.6185 |
|
|
For Anika Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Anika Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Anika Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Anika Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Anika Therapeutics over time as well as its relative position and ranking within its peers.
Anika |
Anika Therapeutics' Revenue Breakdown by Earning Segment
Check out Trending Equities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anika Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.51) | Earnings Share (6.64) | Revenue Per Share 11.139 | Quarterly Revenue Growth (0.07) | Return On Assets (0.04) |
The market value of Anika Therapeutics is measured differently than its book value, which is the value of Anika that is recorded on the company's balance sheet. Investors also form their own opinion of Anika Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Anika Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anika Therapeutics' market value can be influenced by many factors that don't directly affect Anika Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anika Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anika Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Anika Therapeutics Price To Earning vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Anika Therapeutics's current stock value. Our valuation model uses many indicators to compare Anika Therapeutics value to that of its competitors to determine the firm's financial worth. Anika Therapeutics is rated below average in current valuation category among its peers. It is rated fifth in price to earning category among its peers . The ratio of Current Valuation to Price To Earning for Anika Therapeutics is about 5,311,725 . Comparative valuation analysis is a catch-all technique that is used if you cannot value Anika Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Anika Current Valuation vs. Competition
Anika Therapeutics is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is presently estimated at about 7.75 Billion. Anika Therapeutics holds roughly 224.69 Million in current valuation claiming about 2.9% of equities under Health Care industry.
Anika Price To Earning vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Anika Therapeutics |
| = | 224.69 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Anika Therapeutics |
| = | 42.30 X |
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Anika Price To Earning Comparison
Anika Therapeutics is currently under evaluation in price to earning category among its peers.
Anika Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Anika Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Anika Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Anika Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Anika Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -5.9 M | -6.2 M | |
| Operating Income | -87.6 M | -83.3 M | |
| Income Before Tax | -85.3 M | -81.1 M | |
| Net Loss | -82.7 M | -78.5 M | |
| Income Tax Expense | -2.7 M | -2.5 M | |
| Total Other Income Expense Net | 2.3 M | 2.4 M | |
| Net Loss | -17.1 M | -16.2 M | |
| Net Loss | -24.6 M | -23.3 M | |
| Interest Income | 2.2 M | 2.3 M | |
| Net Interest Income | 2 M | 2.1 M | |
| Change To Netincome | 17 M | 17.8 M | |
| Net Loss | (5.64) | (5.36) | |
| Income Quality | 0.02 | 0.02 | |
| Net Income Per E B T | 0.97 | 0.95 |
Anika Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Anika Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Anika Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Anika Therapeutics' important profitability drivers and their relationship over time.
Use Anika Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Anika Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Anika Therapeutics will appreciate offsetting losses from the drop in the long position's value.Anika Therapeutics Pair Trading
Anika Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Anika Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Anika Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Anika Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Anika Therapeutics to buy it.
The correlation of Anika Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Anika Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Anika Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Anika Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Anika Therapeutics position
In addition to having Anika Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run SPAC Thematic Idea Now
SPAC
Entities that are involved in raising capital, merging with and acquiring companies, and investing in private equity through leveraged buyouts. The SPAC theme has 25 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize SPAC Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
To fully project Anika Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Anika Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Anika Therapeutics' income statement, its balance sheet, and the statement of cash flows.